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To the Editor: We have reported a randomised, long-term
safety study comparing the effects of using the insulin
analogue glargine (A21Gly,B31Arg,B32Arg human insulin)
versus human neutral protamine Hagedorn (NPH) insulin for
5 years in the management of type 2 diabetes [1]. The study,
in which 1017 patients were randomised and treated, was
designed to assess ocular complications of diabetes: there
was no excess of such effects with insulin glargine compared
with NPH insulin treatment and there was a similar slow
progression of diabetic retinopathy with both types of
insulin. Because of recent concerns about postulated
neoplastic effects of insulins [2–5], we report here additional
information from our study that bears on this question.
In total, the mean cumulative exposure in our study was
more than 4 years (1,524 days in the insulin glargine group
and 1,522 days in the NPH insulin group), with more than
70% of patients exposed to more than 4 years of treatment
(76% and 71%, respectively) (Table 1).
The baseline demographics and diabetes status were
similar between the two treatment groups (insulin glargine
vs NPH insulin): diabetes duration (10.7 vs 10.8 years),
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2), oral hypoglycaemic agent
duration (9.0 vs 8.9 years), prior insulin use (67% vs
70%), HbA1c (8.4% vs 8.3%) and fasting plasma glucose
(10.5 vs 10.0 mmol/l).
Although the study was not designed to investigate the
frequency of tumour development, the long duration of the
trial enables a comparative assessment of the occurrence of
benign or malignant tumours with insulin glargine and NPH
insulin during more than 4 years of exposure, captured as
adverse events in the course of routine safety monitoring.
The number of patients with treatment-emergent adverse
events (defined as events that first occurred or worsened
after randomisation) of neoplasm, summarised by System
Organ Class and High-level Group Term levels using the
standard Medical Dictionary for Regulatory Activities
(MedDRA) coding dictionary (version 10.0; Maintenance
and Support Services Organization, Chantilly, VA, USA)
[6], are shown in Table 2. Benign and malignant tumours
reported by the investigators, along with those of unspec-
ified pathology, are included. A more detailed listing of
MedDRA-coded neoplasms is available [7].
The overall number of patients with neoplasms (using the
standard MedDRA coding dictionary) occurring during the
trial was similar in the two treatment groups: 57 patients
(11.1%)intheinsulinglarginegroupvs62patients(12.3%)in
theNPHinsulingroup,withanRRforinsulinglargineof0.90
(95% CI 0.64–1.26). In addition, when only the number of
patients with malignant neoplasms reported as serious
Table 2 Patients with neoplasms reported as treatment-emergent adverse events
All neoplasms
a Insulin glargine (n=514) NPH insulin (n=503)
Any event 57 (11.1) 62 (12.3)
Breast neoplasms, malignant 3 (0.6) 5 (1.0)
Cutaneous neoplasms, benign 13 (2.5) 12 (2.4)
Endocrine neoplasms, malignant 5 (1.0) 7 (1.4)
Gastrointestinal neoplasms, malignant 6 (1.2) 9 (1.8)
Haematopoietic neoplasms 1 (0.2) 0
Hepatobiliary neoplasms, malignant 0 1 (0.2)
Lymphomas, non-Hodgkin's B cell 0 1 (0.2)
Metastases, unspecified neoplasm 0 1 (0.2)
Miscellaneous and site unspecified neoplasms, malignant 1 (0.2) 3 (0.6)
Nervous system neoplasms, benign 1 (0.2) 2 (0.4)
Ocular neoplasms, benign or malignant 3 (0.6) 2 (0.4)
Plasma cell neoplasms, benign or malignant 1 (0.2) 0
Renal and urinary tract neoplasms, malignant 2 (0.4) 1 (0.2)
Reproductive neoplasms female, benign 2 (0.4) 1 (0.2)
Reproductive neoplasms female, malignant 2 (0.4) 4 (0.8)
Reproductive neoplasms male, malignant 2 (0.4) 3 (0.6)
Respiratory and mediastinal neoplasms, malignant 6 (1.2) 2 (0.4)
Skin neoplasms, malignant 11 (2.1) 9 (1.8)
Soft tissue neoplasms, benign 3 (0.6) 4 (0.8)
Soft tissue sarcomas, benign or malignant 0 1 (0.2)
Data are n (%), in alphabetical order
All patients with neoplasm-coded adverse events (whether considered serious or non-serious) as reported by the investigator are included. Patients
may have had more than one adverse event
aIncludes MedDRA System Organ Class ‘Neoplasm benign, malignant and unspecified (including cysts and polyps)’ (version 10.0) [6]
Variable Insulin glargine (n=514) NPH insulin (n=503)
Cumulative exposure (patient-years) 2144.0 2095.8
Extent of exposure (days)
Mean 1523.55±571.77 1521.82±562.14
Median 1821.50 1823.00
Table 1 Summary of extent of
exposure (safety population)
Data are mean±SD unless
otherwise stated
1972 Diabetologia (2009) 52:1971–1973treatment-emergent events was captured, the rate was also
similar in both treatment groups: 20 patients (3.9%) with 23
eventsinthe insulin glargine group vs31patients(6.2%)with
32 events in the NPH insulin group, with an RR for insulin
glargine of 0.63 (95% CI 0.36–1.09).
The number of patients with malignant breast tumours
reported was also similar between the two treatment groups:
three patients in the insulin glargine group (all reported as
serious) compared with five patients (four reported as
serious) in the NPH insulin group.
The RR estimate of all malignant breast tumour cases,
including non-serious cases (three in the insulin glargine
group vs five in the NPH insulin group) numerically favours
insulin glargine (RR 0.59, 95% CI 0.14–2.44). Although the
95% CI includes 2, it must be noted that due to the small
numbers of patients and the small number of cases, there was
only a 22% power to reject a doubling in the risk (RR 2.0) of
developing this tumour, should the true risks be equal.
Considering all neoplasms (RR 0.9) and all malignant
neoplasms (RR 0.63), the results numerically favour insulin
glargine with 95% upper CI limits of 1.26 and 1.09,
respectively,indicatingatmosta26%and9%increaseinrisk.
In summary, this study is the longest controlled
treatment comparison of insulin glargine versus NPH
insulin in patients with type 2 diabetes mellitus. No new
safety issues emerged for either insulin studied based on the
data from this 5 year trial. Additional data reported here
also confirm that there was no evidence of any difference in
the rate of benign or malignant tumour development with
insulin glargine compared with NPH insulin.
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